313 related articles for article (PubMed ID: 11945152)
1. Gastrointestinal safety of selective COX-2 inhibitors.
Hawkey CJ; Skelly MM
Curr Pharm Des; 2002; 8(12):1077-89. PubMed ID: 11945152
[TBL] [Abstract][Full Text] [Related]
2. Current perspective on the cardiovascular effects of coxibs.
Konstam MA; Weir MR
Cleve Clin J Med; 2002; 69 Suppl 1():SI47-52. PubMed ID: 12086293
[TBL] [Abstract][Full Text] [Related]
3. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.
Silverstein FE; Faich G; Goldstein JL; Simon LS; Pincus T; Whelton A; Makuch R; Eisen G; Agrawal NM; Stenson WF; Burr AM; Zhao WW; Kent JD; Lefkowith JB; Verburg KM; Geis GS
JAMA; 2000 Sep; 284(10):1247-55. PubMed ID: 10979111
[TBL] [Abstract][Full Text] [Related]
4. Gastrointestinal safety and tolerability of nonselective nonsteroidal anti-inflammatory agents and cyclooxygenase-2-selective inhibitors.
Peura DA
Cleve Clin J Med; 2002; 69 Suppl 1():SI31-9. PubMed ID: 12086291
[TBL] [Abstract][Full Text] [Related]
5. An evidence-based evaluation of the gastrointestinal safety of coxibs.
Bombardier C
Am J Cardiol; 2002 Mar; 89(6A):3D-9D. PubMed ID: 11909555
[TBL] [Abstract][Full Text] [Related]
6. New directions in symptomatic therapy for patients with osteoarthritis and rheumatoid arthritis.
Hochberg MC
Semin Arthritis Rheum; 2002 Dec; 32(3 Suppl 1):4-14. PubMed ID: 12528069
[TBL] [Abstract][Full Text] [Related]
7. Cyclooxygenase-2 inhibition and side-effects of non-steroidal anti-inflammatory drugs in the gastrointestinal tract.
Meyer-Kirchrath J; Schrör K
Curr Med Chem; 2000 Nov; 7(11):1121-9. PubMed ID: 11032962
[TBL] [Abstract][Full Text] [Related]
8. Outcomes studies of the gastrointestinal safety of cyclooxygenase-2 inhibitors.
Scheiman JM
Cleve Clin J Med; 2002; 69 Suppl 1():SI40-6. PubMed ID: 12086292
[TBL] [Abstract][Full Text] [Related]
9. What have we learned from the large outcomes trials of COX-2 selective inhibitors? The rheumatologist's perspective.
Hochberg MC
Clin Exp Rheumatol; 2001; 19(6 Suppl 25):S15-22. PubMed ID: 11695246
[TBL] [Abstract][Full Text] [Related]
10. Gastrointestinal safety of coxibs and outcomes studies: what's the verdict?
Laine L
J Pain Symptom Manage; 2002 Apr; 23(4 Suppl):S5-10; discussion S11-4. PubMed ID: 11992743
[TBL] [Abstract][Full Text] [Related]
11. [Non-steroidal anti-inflammatory agents with selective inhibitory activity on cyclooxygenase-2. Interest and future prospects].
Blain H; Jouzeau JY; Netter P; Jeandel C
Rev Med Interne; 2000 Nov; 21(11):978-88. PubMed ID: 11109595
[TBL] [Abstract][Full Text] [Related]
12. Gastro-duodenal protection in an era of cyclo-oxygenase-2-selective nonsteroidal anti-inflammatory drugs.
Naesdal J; Wilson I
Eur J Gastroenterol Hepatol; 2001 Dec; 13(12):1401-6. PubMed ID: 11742186
[TBL] [Abstract][Full Text] [Related]
13. A comparison of adverse renovascular experiences among osteoarthritis patients treated with rofecoxib and comparator non-selective non-steroidal anti-inflammatory agents.
Gertz BJ; Krupa D; Bolognese JA; Sperling RS; Reicin A
Curr Med Res Opin; 2002; 18(2):82-91. PubMed ID: 12017215
[TBL] [Abstract][Full Text] [Related]
14. The gastrointestinal effects of nonselective NSAIDs and COX-2-selective inhibitors.
Laine L
Semin Arthritis Rheum; 2002 Dec; 32(3 Suppl 1):25-32. PubMed ID: 12528071
[TBL] [Abstract][Full Text] [Related]
15. COX-2 inhibitors vs. NSAIDs in gastrointestinal damage and prevention.
Ballinger A; Smith G
Expert Opin Pharmacother; 2001 Jan; 2(1):31-40. PubMed ID: 11336566
[TBL] [Abstract][Full Text] [Related]
16. Anti-inflammatory drugs in the 21st century.
Rainsford KD
Subcell Biochem; 2007; 42():3-27. PubMed ID: 17612044
[TBL] [Abstract][Full Text] [Related]
17. Review article: the gastrointestinal safety profile of rofecoxib, a highly selective inhibitor of cyclooxygenase-2, in humans.
Hawkey CJ; Jackson L; Harper SE; Simon TJ; Mortensen E; Lines CR
Aliment Pharmacol Ther; 2001 Jan; 15(1):1-9. PubMed ID: 11136272
[TBL] [Abstract][Full Text] [Related]
18. The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events.
Hunt RH; Harper S; Watson DJ; Yu C; Quan H; Lee M; Evans JK; Oxenius B
Am J Gastroenterol; 2003 Aug; 98(8):1725-33. PubMed ID: 12907325
[TBL] [Abstract][Full Text] [Related]
19. Gastrointestinal toxicity of non-steroidal anti-inflammatory drugs: the effect of nimesulide compared with naproxen on the human gastrointestinal tract.
Bjarnason I; Thjodleifsson B
Rheumatology (Oxford); 1999 May; 38 Suppl 1():24-32. PubMed ID: 10369403
[TBL] [Abstract][Full Text] [Related]
20. COX-2 inhibitors and the cardiovascular system.
FitzGerald GA; Cheng Y; Austin S
Clin Exp Rheumatol; 2001; 19(6 Suppl 25):S31-6. PubMed ID: 11695249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
